Glutathione (GSH) is the body's most abundant intracellular antioxidant — a tripeptide that neutralizes oxidative damage, supports detoxification, and is used clinically and off-label for everything from liver protection to skin lightening.
What it does
Glutathione is a three-amino-acid molecule (glutamate-cysteine-glycine) found in virtually every human cell at high concentrations. Its core job is redox defense: the enzyme glutathione peroxidase uses GSH to convert hydrogen peroxide and lipid peroxides — reactive molecules that damage cell membranes and DNA — into harmless water and alcohols. In doing so, GSH itself becomes oxidized (GSSG), then gets recycled back to its active form by glutathione reductase, powered by NADPH.
Beyond direct antioxidant work, GSH is the substrate for glutathione S-transferase (GST), an enzyme family that tags electrophilic (electron-hungry) toxins — including heavy metals, carcinogens, and certain drugs — making them water-soluble so the kidneys and bile can excrete them. This is one of the liver's primary detox pathways. GSH also keeps vitamins C and E in their chemically active, reduced forms, functioning as a hub for the broader antioxidant network. Mitochondrial membranes, which are especially vulnerable to oxidative damage, depend on GSH to maintain energy production.
At high systemic doses, GSH shifts melanin synthesis in skin — the pigment-producing enzyme tyrosinase is inhibited, and the pathway tilts from eumelanin (darker pigment) toward pheomelanin (lighter pigment). This is the mechanism behind its use as a skin-lightening agent. Immune function also tracks GSH status: T-cell proliferation, NK cell activity, and general lymphocyte function decline when GSH is depleted.
What the evidence shows
Antioxidant support and oxidative stress reduction Strong mechanistic evidence; modest direct human trial data
GSH's role as a cellular antioxidant is among the most well-characterized in biochemistry. The recycling loop — GSH → GSSG → GSH via glutathione reductase — is a textbook pathway. Studies in animal models consistently show that GSH depletion amplifies oxidative injury and that repletion reverses it Olia 2025. Human data are thinner: most trials measure GSH levels as a secondary biomarker rather than testing GSH supplementation directly as an intervention. Oral bioavailability of standard glutathione is poor due to gut hydrolysis, which is why liposomal and IV formulations dominate clinical use.
Liver detoxification and drug-induced hepatotoxicity Well-established mechanism; IV use is standard in acetaminophen overdose adjunct care
GSH conjugation via GST is one of the liver's main Phase II detoxification routes. In clinical toxicology, GSH precursor N-acetylcysteine (NAC) is standard of care for acetaminophen overdose precisely because it replenishes hepatic GSH. Direct IV glutathione is used in some protocols for chemotherapy-related neurotoxicity and liver protection, though large randomized controlled trials specifically on exogenous GSH infusion remain limited. The mechanistic case is solid; the RCT evidence base is not.
Immune function Clear cellular mechanism; animal evidence; limited controlled human data
GSH depletion is consistently associated with impaired T-cell proliferation and reduced NK cell activity in cell culture and animal studies V 2025. In humans, low GSH levels have been observed in HIV, sepsis, and aging — populations with known immune dysfunction — but causality is hard to establish from these correlations. Controlled trials showing that exogenous GSH administration meaningfully improves immune outcomes in healthy or immune-compromised people are sparse.
Skin lightening / hyperpigmentation Plausible mechanism; small human trials with mixed results
GSH inhibits tyrosinase (the rate-limiting enzyme in melanin production) and nudges pigment synthesis from darker eumelanin toward lighter pheomelanin at high doses. Several small trials — mostly conducted in Southeast Asia — have reported measurable skin lightening with IV or oral GSH over weeks to months, but sample sizes are small (typically under 60 participants) and blinding is often imperfect. Regulatory agencies in several countries have cautioned against IV glutathione for cosmetic skin lightening given the risk profile at the doses required.
Neuroprotection and neurological conditions Early-stage human research; mostly mechanistic and observational
Oxidative stress plays a documented role in Parkinson's disease, and GSH depletion in the substantia nigra is an early feature of the disease. Small pilot trials of IV GSH in Parkinson's patients reported subjective improvements, but these were unblinded and underpowered. Research into PTSD-related oxidative pathways is ongoing NCT03840369. At this point, neuroprotective applications are hypothesis-generating rather than evidence-based.
How it's used
In studies and self-reported protocols, doses range widely by route. Intravenous (IV) doses typically run 200–400 mg once weekly at the lower end, 600–1000 mg twice weekly for moderate use, and up to 2000 mg twice weekly for skin lightening applications. IV administration is given as a slow push over 5–10 minutes. Subcutaneous (SubQ) and intramuscular (IM) injection are used at similar dose ranges. Oral glutathione has poor bioavailability in standard capsule form due to gut breakdown; liposomal oral formulations partially address this and are used at 250–500 mg daily in self-reported protocols. Nebulized glutathione (inhaled) has been explored for pulmonary applications but carries a risk of bronchospasm, particularly in people with asthma. Plasma half-life is roughly 14 minutes, which is why frequent or IV dosing is favored over standard oral supplementation for clinical effect.
Side effects and safety
IV glutathione is generally well-tolerated at low-to-moderate doses. Mild side effects include nausea, headache, and bloating — more common with oral forms. Skin whitening occurs predictably at higher doses and is the intended outcome in cosmetic use, but counts as an unintended effect otherwise. Chronic use has been linked to zinc depletion, likely through competitive excretion pathways, so zinc monitoring is reasonable in long-term users Mehdi 2025. Rare but serious risks include anaphylaxis with IV administration and Stevens-Johnson syndrome (a severe skin reaction) — both exceedingly rare but documented. Inhaled glutathione can provoke bronchospasm in asthmatics. Long-term safety data on repeated high-dose IV GSH in healthy individuals essentially does not exist; most of what's known comes from short-duration trials or from patients receiving it therapeutically. The cosmetic skin-lightening use at high IV doses sits in a regulatory gray zone in most countries, and several health agencies have issued warnings about it.
Bottom line
Glutathione has one of the strongest mechanistic rationales in the antioxidant world — its cellular roles are well-understood and genuinely important. However, translating that into a clinical case for exogenous supplementation is harder than the mechanism implies: oral bioavailability is limited, and large human RCTs are mostly absent. IV use for specific indications like hepatotoxicity support has the best backing; cosmetic skin lightening has the most risk relative to evidence quality.